Can a common acid reflux drug protect Children's airways?
NCT ID NCT07750379
First seen Aug 06, 2026 · Last updated Aug 07, 2026 · Updated 1 time
Summary
This trial tests whether giving a proton pump inhibitor (PPI) to children with laryngomalacia—a common birth defect of the voice box—can reduce the chance of food or liquid entering the airway (aspiration). Children aged 6 months to 5 years with recurrent choking or aspiration symptoms will be randomly assigned to receive PPI therapy or standard care. Researchers will compare aspiration rates and swallowing outcomes between the two groups to see if the medication helps.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Proton pump inhibitor (esomeprazole) therapy, vitamin D supplementation, and standard feeding instructions
- What this could lead to
- If effective, this could establish PPI therapy as a standard way to lower aspiration risk and improve swallowing outcomes in children with laryngomalacia.
- What could go wrong
- The trial is small (60 children) and early, so results may not apply broadly. PPIs carry potential side effects, and the study's findings may not confirm a clear benefit.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LARYNGOMALACIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
faculty of Medicine, Minia University
RECRUITINGMinya, Minya Governorate, Egypt